EC Number   |
Title |
Organism |
|---|
    2.1.1.45 | Alanine mutants of the interface residues of human thymidylate synthase decode key features of the binding mode of allosteric anticancer peptides |
Homo sapiens |
| 2.1.1.45 | Bacterial thymidylate synthase binds two molecules of substrate and cofactor without cooperativity |
Escherichia coli |
| 2.1.1.45 | Bacterial versus human thymidylate synthase Kinetics and functionality |
Homo sapiens |
| 2.1.1.45 | Biochemical characterization of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase from Leishmania (Viannia) and its evaluation as a drug target |
Leishmania braziliensis |
| 2.1.1.45 | Biochemical characterization of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase from Leishmania (Viannia) and its evaluation as a drug target |
Trypanosoma cruzi |
| 2.1.1.45 | Biochemical characterization of the bifunctional enzyme dihydrofolate reductase-thymidylate synthase from Leishmania (Viannia) and its evaluation as a drug target |
Leishmania panamensis |
| 2.1.1.45 | Crystal structure of the active form of native human thymidylate synthase in the absence of bound substrates |
Homo sapiens |
| 2.1.1.45 | Design, synthesis and biological evaluation of N-phenyl-(2,4-dihydroxypyrimidine-5-sulfonamido)benzoyl hydrazide derivatives as thymidylate synthase (TS) inhibitors and as potential antitumor drugs |
Homo sapiens |
| 2.1.1.45 | Design, synthesis and biological evaluation of novel uracil derivatives bearing 1, 2, 3-triazole moiety as thymidylate synthase (TS) inhibitors and as potential antitumor drugs |
Homo sapiens |
| 2.1.1.45 | Design, synthesis, anticancer evaluation and docking studies of new pyrimidine derivatives as potent thymidylate synthase inhibitors |
Homo sapiens |
